Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Osteotech has announced that the US Patent and Trademark Office has confirmed the validity of its US patent that covers mixtures of a radiolucent material, such as demineralized bone, with a radiopaque material, such as nondemineralized or partially demineralized bone, that is provided in sufficient quantity to be used as a radiographic marker.
Subscribe to our email newsletter
Sam Owusu-Akyaw, president and CEO of Osteotech, said: “The ‘146 patent is an important part of our strategic vision providing patent protection for certain of our current Grafton DBM products and for our next generation DBM products currently under development. It is our patent protection that allows us to make the investments necessary to continue to develop superior products for the medical community and patient care.”